

Belbuca - (300 mcg, 450 mcg, 600 mcg and 750 mcg; Film Buccal)

| | | | |
|------------------------------|---|-----------------------------|----------------------|
| Generic Name | Buprenorphine Hydrochloride | Innovator | Biodelivery Sciences |
| Dosage | 300 mcg, 450 mcg, 600 mcg and 750 mcg; Film Buccal | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Belbuca - (900 mcg; Buccal film)

| | | | |
|------------------------------|---|-----------------------------|----------------------|
| Generic Name | Buprenorphine Hydrochloride | Innovator | Biodelivery Sciences |
| Dosage | 900 mcg; Buccal film | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Belbuca - (75 mcg and 150 mcg ; Buccal film)

| | | | |
|------------------------------|---|-----------------------------|----------------------|
| Generic Name | Buprenorphine Hydrochloride | Innovator | Biodelivery Sciences |
| Dosage | 75 mcg and 150 mcg ; Buccal film | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.